Michael E. Wechsler, MD

Michael Wechsler, MD, is a fellowship-trained pulmonologist who specializes in asthma, eosinophilic lung diseases, EGPA, and idiopathic hypereosinophilic syndrome at National Jewish Health.

Articles by Michael E. Wechsler, MD

Anti-IL-5 Drugs Cut Steroid Use in EGPA: Michael Wechsler, MD, MMSc

ByMichael E. Wechsler, MD,Sabrina McCrear

October 5th 2026

Michael Wechsler, MD, MMSc, explains how anti-IL-5 therapies studied in the MIRRA and MANDARA trials are reducing steroid use in EGPA.

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

BySabrina McCrear,Michael E. Wechsler, MD

October 2nd 2026

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma.

ATS 2026 Highlighted Collaboration and Innovation in Pulmonary Medicine

BySabrina McCrear,Njira L. Lugogo, MD, MS,Mark Metersky, MD,Jerry A. Krishnan, MD, PhD,Yet Khor, MD, PhD,Michael E. Wechsler, MD

May 27th 2026

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

Michael Wechsler, MD, MMSc, discussed how tezepelumab may address multiple severe asthma outcomes simultaneously.

Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc

BySabrina McCrear,Michael E. Wechsler, MD

May 19th 2026

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc

BySabrina McCrear,Michael E. Wechsler, MD

May 19th 2026

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies

ByDonald A. Bukstein, MD,Craig A. Jones, MD,Dennis K. Ledford, MD,Peter Smith, MD,Michael E. Wechsler, MD,Frank L. Urbano, MD, FACP

October 17th 2005

Latest Updated Articles

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies
October 17th 2005

Michael E. Wechsler, MD

Articles by Michael E. Wechsler, MD

Anti-IL-5 Drugs Cut Steroid Use in EGPA: Michael Wechsler, MD, MMSc

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

ATS 2026 Highlighted Collaboration and Innovation in Pulmonary Medicine

Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc

SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies

Latest Updated Articles

Trending on AJMC

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease

Extension Studies in TPIP Show Promise in PAH, PH-ILD

Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD

Managed Care Keeps Pace With Policy as AMCP Nexus Heads to San Diego

The Bispecifics Network:

Advancing Bispecific Care Delivery in Community Oncology

Michael E. Wechsler, MD

Articles by Michael E. Wechsler, MD

Anti-IL-5 Drugs Cut Steroid Use in EGPA: Michael Wechsler, MD, MMSc

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

ATS 2026 Highlighted Collaboration and Innovation in Pulmonary Medicine

Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc

SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies

Latest Updated Articles

Trending on AJMC

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease

Extension Studies in TPIP Show Promise in PAH, PH-ILD

Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD

Managed Care Keeps Pace With Policy as AMCP Nexus Heads to San Diego